{
  "scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 0,
        "evidence": "Background: We studied the maximum tolerated dose (MTD) and efficacy of oxaliplatin added to capecitabine and radiotherapy (Capox-RT) as neoadjuvant therapy for rectal cancer."
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "Methods: T3-4 rectal cancer patients received escalating doses of oxaliplatin (day 1 and 29) with a fixed dose of capecitabine of 1000 mg/m 2 twice daily (days 1\u201314, 25\u201338) added to RT with 50.4 Gy and surgery after 6\u20138 weeks."
      },
      "Participants": {
        "score": 1,
        "evidence": "Methods: T3-4 rectal cancer patients received escalating doses of oxaliplatin (day 1 and 29) with a fixed dose of capecitabine of 1000 mg/m 2 twice daily (days 1\u201314, 25\u201338) added to RT with 50.4 Gy and surgery after 6\u20138 weeks."
      },
      "Intervention": {
        "score": 2,
        "evidence": "Methods: T3-4 rectal cancer patients received escalating doses of oxaliplatin (day 1 and 29) with a fixed dose of capecitabine of 1000 mg/m 2 twice daily (days 1\u201314, 25\u201338) added to RT with 50.4 Gy and surgery after 6\u20138 weeks."
      },
      "Objective": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The MTD, determined during phase I, was used in the subsequent phase II, in which R0 resection rate (a negative circumferential resection margin) was the primary end point."
      },
      "Randomisation_Allocation": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Blinding": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Number_Randomised": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "Results: Twenty-one patients were evaluable."
      },
      "Result_Outcome": {
        "score": 2,
        "evidence": "An R0 was achieved in 17/21 patients, downstaging to T0-2 in 7/21 and a pCR in 2/21."
      },
      "Harms": {
        "score": 1,
        "evidence": "In phase II, the main toxicity was grade III diarrhea (18%)."
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Funding": {
        "score": 0,
        "evidence": "Not reported"
      }
    },
    "total_score": 10,
    "max_score": 25
  },
  "model": "gpt-4o"
}